Timor-Leste vs Viet Nam: Prevalence rate of obesity in adults
Timor-Leste
3.6%
in 2024
Viet Nam
2.4%
in 2024
Timor-Leste rank
197th
Viet Nam rank
199th
Prevalence rate of obesity in adults over time
- Timor-Leste
- Viet Nam
How they compare
Timor-Leste currently reports 3.6% against 2.4% in Viet Nam, a difference of 1.2%.
That makes Timor-Leste's figure about 1.5 times Viet Nam's.
The two have swapped places 1 time across 45 shared years of data; in 1980 it was Viet Nam ahead.
Timor-Leste ranks 197th and Viet Nam ranks 199th of 199 countries.
Timor-Leste has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | Timor-Leste | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 0.2% | 0.2% | 0.0% | Timor-Leste |
| 1990s | 0.4% | 0.2% | 0.1% | Timor-Leste |
| 2000s | 0.7% | 0.4% | 0.3% | Timor-Leste |
| 2010s | 1.6% | 1.1% | 0.5% | Timor-Leste |
| 2020s | 3.1% | 2.1% | 1.0% | Timor-Leste |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Timor-Leste or Viet Nam?
- Timor-Leste, at 3.6% against 2.4% in Viet Nam as of 2024.
- What is the difference in prevalence rate of obesity in adults between Timor-Leste and Viet Nam?
- 1.2%, with Timor-Leste ahead.
- How many years of comparable data are there for Timor-Leste and Viet Nam?
- 45 years are reported by both, from 1980 to 2024.
- How do Timor-Leste and Viet Nam rank globally for prevalence rate of obesity in adults?
- Timor-Leste ranks 197th and Viet Nam ranks 199th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.